Clinical Trials on Components of REAL Essentials in New Zealand

Total 110 results

  • GI Innovation, Inc.
    Merck Sharp & Dohme LLC
    Recruiting
    GI-101 as a Single Agent or in Combination With Pembrolizumab, Lenvatinib or Local Radiotherapy in Advanced Solid Tumors
    Melanoma | Sarcoma | Renal Cell Carcinoma | Cervical Cancer | Urinary Bladder Cancer | Vulvar Cancer | Advanced Solid Tumor | Metastatic Solid Tumor | Non-small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Esophageal Squamous Cell Carcinoma | Merkel Cell Carcinoma | Vaginal Cancer | Microsatellite Stable...
    Korea, Republic of, United States
  • Novartis Pharmaceuticals
    Recruiting
    A Study of Safety and Efficacy of KFA115 Alone and in Combination With Pembrolizumab in Patients With Select Advanced Cancers
    Carcinoma, Renal Cell | Carcinoma, Non-Small-Cell Lung | Nasopharyngeal Carcinoma | Carcinoma, Ovarian Epithelial | Mesothelioma | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Anal Cancer | Cutaneous Melanoma | Esophagogastric Cancer | Carcinoma, Thymic | High Microsatellite...
    Italy, Spain, Singapore, Germany, Taiwan, Japan, Canada, Hong Kong, United States
  • ImmunityBio, Inc.
    Active, not recruiting
    QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors
    Melanoma | Renal Cell Carcinoma | Cervical Cancer | Small Cell Lung Cancer | Hepatocellular Carcinoma | Gastric Cancer | Colorectal Cancer | Non-Small Cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Urothelial Carcinoma | Merkel Cell Carcinoma | Microsatellite Instability | Mismatch Repair Deficiency
    United States
  • Celldex Therapeutics
    Completed
    A Study of CDX-1127 (Varlilumab) in Patients With Select Solid Tumor Types or Hematologic Cancers
    Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | CD27 Expressing B-cell Malignancies for Example Hodgkin's Lymphoma | Marginal Zone B Cell Lymphoma) | Any T-cell Malignancy | Solid Tumors (Metastatic Melanoma, Renal (Clear) Cell Carcinoma | Hormone-refractory Prostate Adenocarcinoma, Ovarian... and other conditions
    United States
  • SOTIO Biotech AG
    SOTIO Biotech a.s.
    Active, not recruiting
    Study of SO-C101 and SO-C101 in Combination With Pembro in Adult Patients With Advanced/Metastatic Solid Tumors
    Melanoma | Renal Cell Carcinoma | Cervical Cancer | Hepatocellular Carcinoma | Gastric Cancer | Ovarian Cancer | Non Small Cell Lung Cancer | Mesothelioma | Bladder Cancer | Triple Negative Breast Cancer | Small-cell Lung Cancer | Head and Neck Squamous Cell Carcinoma | Thyroid | Anal Cancer | Merkel Cell Carcinoma | Biliary... and other conditions
    United States, France, Spain, Czechia
  • Medicenna Therapeutics, Inc.
    Merck Sharp & Dohme LLC
    Recruiting
    A Beta-only IL-2 ImmunoTherapY Study (ABILITY-1)
    Clear Cell Renal Cell Carcinoma | Cervical Cancer | Gastric Cancer | Esophageal Cancer | Ovarian Cancer | Fallopian Tube Cancer | Solid Tumor | Squamous Cell Carcinoma of Head and Neck | Bladder Cancer | Skin Cancer | Triple Negative Breast Cancer | Advanced Solid Tumor | Primary Peritoneal Cancer | Endometrial Carcinoma and other conditions
    United States, Australia, Korea, Republic of, Canada
  • Bristol-Myers Squibb
    Recruiting
    A Study of BMS-986340 as Monotherapy and in Combination With Nivolumab or Docetaxel in Participants With Advanced Solid Tumors
    Melanoma | Carcinoma, Renal Cell | Cervical Cancer | Pancreatic Adenocarcinoma | Ovarian Neoplasms | Squamous Cell Carcinoma of Head and Neck | Triple Negative Breast Neoplasms | Urothelial Carcinoma | Microsatellite Stable Colorectal Cancer | Non-Small-Cell Lung Cancer | Gastric/Gastroesophageal Junction...
    United States, Australia, Italy, Germany, Spain, Canada, Israel, Japan
  • Actuate Therapeutics Inc.
    Active, not recruiting
    9-ING-41 in Patients With Advanced Cancers
    Sarcoma | Cancer | Breast Neoplasms | Neoplasm Metastasis | Pancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Bone Cancer | Malignant Glioma | Bone Metastases | Pancreas Cancer | Renal Cancer | Refractory Non-Hodgkin Lymphoma | Bone Neoplasm | Neoplasm, Breast | Refractory Cancer | Refractory Neoplasm | Resistant... and other conditions
    United States, Belgium, Canada, Spain, France, Netherlands, Portugal
  • Xencor, Inc.
    ICON Clinical Research
    Completed
    A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors (DUET-4)
    Melanoma | Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Fallopian Tube Cancer | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Triple Negative Breast Cancer | Epithelial Ovarian Cancer | Intrahepatic Cholangiocarcinoma and other conditions
    United States
  • Xencor, Inc.
    ICON plc
    Active, not recruiting
    A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)
    Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditions
    United States

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovenia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

3
Subscribe